![]() ![]() Differentiated technology, based on the technology that distinguishes an innovator from its competitors.Focus/value propositionof the innovator, based on Deloitte’s vision for the Future of Health business models.Quantitative analysis: We analyzed Rock Health data on venture capital deals in health tech between 20. We employed a two-pronged research approach: To that end, we analyzed where investors-traditional VC firms and CVCs-are placing their bets in the Future of Health. Moreover, it can indicate future market performance and emerging trends. Venture funding is often considered an important barometer of innovators’ value propositions and long-term success. Even as the economy and industries, including the health care industry, reel under the impact of the COVID-19 pandemic, venture funding for these innovators nearly doubled in 2020, compared to 2019 (figure 1). ![]() In 2020, venture funding for health tech innovators crossed a record US$14 billion. Growth in venture capital funding for health tech innovators, at record levels in 2020, will likely continue unabated in 2021 However, it is imperative for investors, including industry incumbents, to coach innovators and support them with industry and regulatory expertise, in addition to capital, to accelerate toward the Future of Health together. Innovators could bring transformative business models and a consumer-centric approach. Investors, especially CVCs, can support the innovators and the industry in general. These include demonstrating effectiveness and market opportunity beyond pilots, managing sales cycles and capital, and navigating regulations-to sustain and thrive in this future.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |